<unk>  is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adults treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Lipegfilgrastim
Filgrastim
Pegfilgrastim
Romiplostim
Interferon beta-1a
Granulocyte colony-stimulating factor
Granulocyte-macrophage colony-stimulating factor
Rituximab